Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
A federal advisory panel backed a proposed Johnson & Johnson diabetes drug amid concerns by some panel members about potential cardiovascular risks and less benefit in patients with impaired kidneys.
Janssen Research and Development, LLC, part of J&J, is seeking U.S. Food and Drug Administration approval of a drug called canagliflozin, to treat type 2 diabetes, the common form of the disease.
As part of the approval process, canagliflozin was reviewed Thursday by the FDA's endocrinologic and metabolic drugs advisory committee, which is made up of non-FDA medical experts. The panel voted 10 to 5 saying J&J submitted sufficient data to support marketing of the drug. The company is proposing to sell the drug under the brand name Invokana if approved.
http://www.lloyds.com/news-and-insi...82/fda-panel-backs-proposed-j-j-diabetes-drug
Janssen Research and Development, LLC, part of J&J, is seeking U.S. Food and Drug Administration approval of a drug called canagliflozin, to treat type 2 diabetes, the common form of the disease.
As part of the approval process, canagliflozin was reviewed Thursday by the FDA's endocrinologic and metabolic drugs advisory committee, which is made up of non-FDA medical experts. The panel voted 10 to 5 saying J&J submitted sufficient data to support marketing of the drug. The company is proposing to sell the drug under the brand name Invokana if approved.
http://www.lloyds.com/news-and-insi...82/fda-panel-backs-proposed-j-j-diabetes-drug